Biomedical Research

Objective: To investigate the combinational effect of Endostar bolus infusion and chemotherapy on the level of serum Vessel Epithelium Growth Factor (VEGF), circulating endothelial cells and endostatinin small cell lung cancer patients.

Materials and Methods: From January, 2011 to December, 2014, 30 patients who were diagnosed as IIIIV stage of small cell lung cancer were referred to our hospital. All patients were divided randomly and evenly into three groups: chemotherapy group (Group A), Endostar conventional infusion/ chemotherapy group (Group B) and Endostar bolus infusion/chemotherapy group (Group C). The level of VEGF, circulating endothelial cells and endostatin in serum of all patients were detected by Enzyme- Linked Immunosorbent Assay (ELISA).

Results: After 4 w of treatment, the endostatin level of patients in group C increased, while the level of VEGF and circulating endothelial cells in their serum decreased. But there was no significance found when compared with patients in groups A and B (P>0.05). However, after 8 and 12 w of treatment, the difference between group C and groups A and B became significant (P<0.05).

Conclusion: This study revealed that combination of Endostar bolus infusion and chemotherapy can increase the endostatin level, and decrease the level of VEGF and circulation endothelial cells in serum of small cell lung cancer patients, which suggests that the combination of endostar bolus infusion and chemotherapy can inhibit angiogenesis in small lung cancer.

Author(s): Shaorong Gao, Airong Wang, Guangming Wang, Hongyan Xu, Junlei Yin, Hui Guo, Chengcun Song, Lin Li, Haiping Xia
Abstract | Full-Text | PDF

Share this